Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07443137) titled 'CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)' on Feb. 24.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Stanford University

Condition: Large-cell Lymphoma

Intervention: Biological: Rapcabtagene autoleucel (YTB323)

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: May 2026

Target Sample Size: 20

To know more, visit https://clinicaltrials.gov/study/NCT07443137

Published by HT Digital Content Services with pe...